These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19622902)

  • 1. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
    Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
    Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
    Su X; Lacouture ME; Jia Y; Wu S
    Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
    Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
    Hollywood E
    Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
    Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
    Giuliani J; Marzola M
    J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
    Guo GF; Xia LP; Zhang B; Jiang WQ; Liu MZ; Hu PL; Chen XX; Qiu HJ; Zhou FF
    Ai Zheng; 2009 Dec; 28(12):1317-23. PubMed ID: 19958628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 13. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
    Jatoi A; Nguyen PL
    Oncologist; 2008 Nov; 13(11):1201-4. PubMed ID: 18988655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S; Gonella S; Alessandra B; Palese A
    Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.
    Ma AT; Ma BB; Lei KI; Mo FK; Chan AT
    Hong Kong Med J; 2010 Jun; 16(3):207-12. PubMed ID: 20519757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rash correlates with tumour response after cetuximab.
    Susman E
    Lancet Oncol; 2004 Nov; 5(11):647. PubMed ID: 15536688
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
    Wei F; Shin D; Cai X
    Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
    Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
    Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
    J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.